Global Deoxyribonucleic Acid (DNA) Vaccines Market, By Type (Human DNA Vaccines, Animal DNA Vaccines), technology (pDNA Vaccines Technology, pDNA Delivery Technology), Application (Human Diseases, Veterinary Diseases Allergies, Others), End-User (Human Health, Animal Health, Research Application), Therapeutic Indications (Vector Borne Disease, Cancer), Type of Vaccines (Genetic Vaccines, Recombinant Protein Vaccines) – Industry Trends and Forecast to 2030.
Deoxyribonucleic Acid (DNA) Vaccines Market Analysis and Size
An increase in the rapid development of immunology and molecular biology is the essential factor accelerating the market growth. Furthermore, the development of novel vaccines using DNA technology and increased growth potential in developing economies create an opportunity for manufacturers to tap and invest in the market. Furthermore, it has been noticed that veterinary hospitals held the largest market share in 2020 and are anticipated to remain dominant throughout the forecast period.
Data Bridge Market Research analyses that the deoxyribonucleic acid (DNA) vaccines market, which was USD 465.60 million in 2022, would rise to USD 800 million by 2030 and is expected to undergo a CAGR of 7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Deoxyribonucleic Acid (DNA) Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Human DNA Vaccines, Animal DNA Vaccines), technology (pDNA Vaccines Technology, pDNA Delivery Technology), Application (Human Diseases, Veterinary Diseases Allergies, Others), End-User (Human Health, Animal Health, Research Application), Therapeutic Indications (Vector Borne Disease, Cancer), Type of Vaccines (Genetic Vaccines, Recombinant Protein Vaccines)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Serum Institute of India Pvt. Ltd (India), Fotona (U.S.). GC Biopharma (South Korea), Sanofi (France), Zoetis (U.S.)., INOVIO Pharmaceuticals (U.S.)., General Electric (U.S.), Biomay AG (Austria), Valneva SE (France)
|
|
Market Opportunities
|
|
Market Definition
DNA vaccine is a technology that usually uses foreign DNA to encode the protein and boost the body's immune system. It is a very important way to get protection against numerous infectious diseases. pDNA vaccine technology and pDNA delivery technology are common techniques used in DNA vaccines. Also, these DNA are widely available for both human and veterinary use.
Global Deoxyribonucleic Acid (DNA) Vaccines Market Dynamics
Drivers
- Increasing Prevalence of Cancer
Cancer is a top cause of death worldwide, resulting in approximately 10 million deaths in 2020, or nearly one in six. The most common cancers are lung, breast, colon, rectum, and prostate. Around 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding non-melanoma skin cancer) occurred in 2020. Total incidence was 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, while the death rate varied <2-fold for men and little for women. This increasing prevalence demands the high use of DNA vaccines. This factor leads to the growth of the market.
Opportunities
- Growing Elderly Population
The growing geriatric population is anticipated to expand the market during 2023-2030. According to the World Health Organization (WHO), the global elderly population, anticipated to be more than 524 million in 2010, is expected to increase to around 2 billion by 2050. Geriatrics are more susceptible to pathogenic diseases because of their compromised immune systems, which increases the market growth rate. Thus, this factor boosts market growth.
- Growing Adoption of DNA Vaccines Over Traditional Methods
In the case of several infectious diseases, DNA vaccines offer many potential advantages over traditional approaches, including stimulating both B- and T-cell responses, it improved vaccine stability, and also simplified the procedure by large-scale manufacture. As a result, DNA vaccines are anticipated to enhance the market in the upcoming years. Therefore, this factor serves as a major factor that increases market growth.
Restraints/Challenges
- Inadequate Experience With the Side Effects of DNA Vaccines
Even though DNA vaccines have gained huge importance in upcoming years, it has a few drawbacks as scientists have little knowledge about using them. Human trials are currently being carried out. These are some of the recent limitations of DNA vaccines, which are anticipated to slow down the market. Thus, this factor impedes market growth.
This deoxyribonucleic acid (DNA) vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the deoxyribonucleic acid (DNA) vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Deoxyribonucleic Acid (DNA) Vaccines Market Scope
The deoxyribonucleic acid (DNA) vaccines market is segmented on the basis of type, technology, application, end-user, therapeutic indications and types of vaccines. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Human DNA Vaccines
- Animal DNA Vaccines
Technology
- pDNA Vaccines Technology
- Therapeutic Technology
- Preventive Technology
- pDNA Delivery Technology
- Liposomes
- Uncomplexed pdna
- Gold particles
- Electroporation
- Bacteriophages
- Bacterial ghosts
- Nanoparticles
- Viruses
Application
- Human Diseases
- Veterinary Disease
- Allergies
- Others
End User
- Human Health
- Animal Health
- Research Application
Therapeutic Applications
- Vector Borne Disease
- Cancer
Type of Vaccines
- Genetic Vaccines
- Recombinant Protein Vaccines
Deoxyribonucleic Acid (DNA) Vaccines Market Regional Analysis/Insights
The deoxyribonucleic acid (DNA) vaccines market is analyzed and market size insights and trends are provided by type, technology, application, end-user, therapeutic indications, and types of vaccines as referenced above.
The countries covered in the deoxyribonucleic acid (DNA) vaccines market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period in the deoxyribonucleic acid (DNA) vaccines market due to the well-established veterinary healthcare infrastructure in the region. Also, the wide presence of major market players and the wide presence of well-established veterinary organizational structures lead to market growth.
North America dominates the market in the forecast due to an increase in the rapid development in immunology and molecular biology increase in cases of HIV, cancer, hepatitis, and others. Also, huge growth in government investment in DNA vaccines and a surge in antibiotic-resistant pathogens have necessitated effective and low-cost vaccination in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The deoxyribonucleic acid (DNA) vaccines market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for deoxyribonucleic acid (DNA) vaccines market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the deoxyribonucleic acid (DNA) vaccines market. The data is available for historic period 2011-2021.
Competitive Landscape and Deoxyribonucleic Acid (DNA) Vaccines Market Share Analysis
The deoxyribonucleic acid (DNA) vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to deoxyribonucleic acid (DNA) vaccines market.
Some of the major players operating in the deoxyribonucleic acid (DNA) vaccines market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Serum Institute of India Pvt. Ltd (India),
- Fotona (U.S.)
- G.C. Biopharma (South Korea)
- Sanofi (France), Zoetis (U.S.).
- INOVIO Pharmaceuticals (U.S.).
- General Electric (U.S.)
- Biomay AG (Austria)
- Valneva SE (France)
SKU-